Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and Overseas businesses. The Domestic Business covers the manufacturing, research, and development operations in Japan. The Overseas business comprises of sales and production in Europe, Taiwan and China. The company was founded by Juzo Ueno on March 10, 1925 and is headquartered in Tokyo, Japan.

Enzyvant Therapeutics GmbH, a subsidiary of Sumitomo Chemical Co., Ltd., is a company headquartered in Basel, Switzerland, that operates as a biotechnology company which focuses on developing treatments for rare diseases. William T. Symonds is the current CEO, occupying that position since 2022.

OncoStem Diagnostics Private Limited is Mauritius incorporation with subsidiaries in India and US. It is founded by Cell Biology veteran with significant experience in US, Singapore and India in cancer biology & cancer drug discovery. Of the many challenges in medicine, none has experienced more hard-fought progress than the treatment and cure of cancer. ‘Recurrence’ of cancer is still the single most feared feature of cancer by the patients and oncologists since it is often the cause of morbidity and mortality associated with the disease. Risk of recurrence can vary from cancer to cancer. Accurate prediction of ‘risk of recurrence’ is one of the most important features required to plan optimum and effective treatment. At present, most cancer patients get surgery plus chemotherapy and radiation therapy to prevent cancer recurrence. These treatments are very generic, have severe side effects which reduce quality of life of patients. Finding targeted drugs (e.g. Gleevec, Herceptin) to prevent recurrence is the need of the hour. OncoStem is focussing on these two main issues viz predicting risk of recurrence and developing new targeted drugs to alleviate pain of cancer patients through improved diagnostics. OncoStem is developing novel diagnostic tests which will predict ‘risk of recurrence’ and prescribe targeted drugs to prevent cancer recurrence. Their first focus is breast cancer.

Part of Danaher Corp., Leica Biosystems Melbourne Pty Ltd. is an Australian company located in Mt. Waverley. The firm manufactures and distributes reagents and consumable.

Enzyvant Therapeutics, Inc. develops biopharmaceutical products. It focuses on developing transformative therapies for rare diseases with high unmet needs. The company is headquartered in Cambridge, MA.

Meio Technology (Guangzhou) Co., Ltd., established on 2019-05-13, Business scope includes engineering and technology research and experimental development;Development of Human Gene Diagnosis and Therapy Technology;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Computer System Services;software development;Artificial intelligence basic software development;marketing planning;Corporate Image Planning;Conference and Exhibition Services;Advertising Design,acting;advertisement making;advertising(non-broadcasting station,television station,Newspaper Publishing Unit);Human stem cell technology development and application;R&D and application of cell technology;Sales of Class II Medical Devices;Sales of Class I Medical Devices;Medical Research and Experimental Development;Information Consulting Service(Not including licensing information consulting services);Information Technology Consulting Services;Sales of hygiene products and single-use medical products;Wholesale of protective equipment for medical staff;daily mask(non-medical)Sales;Wholesale medical masks;Remote Health Management Services;Health Consulting Services(Does not include medical services);data processing services;Data processing and storage support services;Natural science research and experimental development;Blockchain technology related software and services;Manufacturing of medical packaging materials;Production of Class I Medical Devices;Manufacturing of Specialty Chemical Products(Free of Hazardous Chemicals);Manufacturing of daily chemical products;Import and export;Technology Import and Export;Production of Class II Medical Devices;Production of Class III Medical Devices;Class III medical device business;Production of hygiene products and single-use medical products;medical service;Inspection and testing service

The Georgia Tech Research Corp. provides research and technology support services. Its services include accounting and reports, researcher and operational support services. The comapny was founded by Preston S. Arkwright, Fuller E. Callaway, Jr. and Monie A. Ferst on April 13, 1937 and is headquartered in Atlanta, GA.

Pharmacia Corp. developed, manufactured and marketed pharmaceutical products. Prescription pharmaceuticals included general therapeutics, ophthalmology and hospital products including oncology and diversified therapeutics. It also operated in consumer health care, animal health, diagnostics and contract manufacturing and bulk pharmaceutical chemicals. The customers of the group were pharmacies, hospitals, chain warehouses, governments, physicians, wholesalers and other distributors. It was headquartered in Peapack, NJ.

Genetics Institute is a U.S. based biotechnology research and development company. The company developed drugs such as Neumega and Recombinate used in the prevention of severe reductions in the number of blood clotting cells. The company was founded in 1980 by Thomas Maniatis and Mark Ptashne, and started off by operating out of Ptashne’s home. Genetics Institute was acquired by Wyeth in 1992 and operates as part of Wyeth’s research division.

Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases, multiple sclerosis, immunology, and oncology. They help people with debilitating and complex conditions that are often difficult to diagnose and treat. They are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. Genzyme became part of Sanofi in 2011. While continuing to focus on rare diseases, they also established ourselves as a leader in the field of multiple sclerosis. In 2016, their focus expanded to include Sanofi’s programs in oncology and immunology. Their approach is shaped by a long history of developing highly specialized treatments and forging close relationships with physician and patient communities. Founded as Genzyme in Boston in 1981, they rapidly grew to become one of the world’s leading biotechnology companies, recognized for their pioneering development of treatments for rare genetic disorders and their innovative contributions to medical science and biomanufacturing.

Merial, Inc. develops pharmaceutical products and vaccines for pets and wildlife. It provides healthcare products and food for dogs, cats, cattle, horse, and poultry producers. The company was founded in August 1997 and is headquartered in Duluth, GA.

MedDay is an international pioneering fully integrated biopharmaceutical company. At MedDay, they believe that it is possible to treat neurodegenerative diseases by targeting key neurometabolic pathways. They strive to develop neuro repair disease modifying therapies and to provide solutions to patients, their caregivers and the healthcare community, in order to improve patient care in areas of high unmet medical need. Promising clinical trial outcomes have encouraged us to date, and are continuing to drive us to pursue this direction. In daring to explore disrupted metabolic pathways in the central nervous system, their teams push the limits to improve future treatment options for patients suffering from neurodegenerative diseases.

Sugen is a biotechnology company that specializes in target-driven drug discovery and development for novel development-stage cancer therapies. It develops new therapeutic approaches to various diseases through its development of small molecule inhibitors that regulate particular signaling pathways. Sugen owns three anti-cancer drugs in clinical development, including novel cytostatic agents and angiogenesis inhibitors. In addition to its current focus in oncology, Sugen is applying its technology platform to identify and validate novel targets for a range of potential clinical applications.

Liaoning Yuhang Biomedical Technology Co., Ltd., established on 2017-05-03, Business scope includes biological products,medical instruments,Technology development and technical services in the field of electronics;Computer software and hardware development;biological products,medical instruments,electronic product,Office Supplies,Daily necessities,communication equipment,knitted goods,Packaging Materials,crafts,cosmetic,Health products,medicine,Rubber products,Agricultural and sideline products,Chemical raw materials and products(Free of Hazardous Chemicals)production,Sales;Business Consulting,Exhibition Consulting,market research,account Serive;Self-operated and agent import and export of various commodities and technologies,Except for the goods and technologies that the state restricts the company to operate or prohibits the import and export of.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments.)

Rubin Medical develops device tracking and navigation technology for the healthcare industry. They provide endoscout and motionscout products. Their endoscout system provides a plug-and-track system and accessories that are compatible with MRI scanners and allows tracking and navigation of devices during an MRI scan. Their endoscout system enables tracking of the location and orientation of miniature sensors during an MRI scan.

Primo Biotechnology harnesses advanced molecular imaging and radiopharmaceutical science to provide precise clinical information via targeted radiopharmaceuticals. Primo Biotechnology aims to form a patient-centric healthcare model and establish doctor-patient relationships founded on trust towards conveying hope and happiness to all patients.

iGene Sdn. Bhd. provides technology solutions fro forensic medicine. Its digital autopsy is a software based procedure utilizing the power of imaging and visualization to conduct autopsy on a digital body. The company was founded by Mathavan A. Chandran in 2000 and is headquartered in Mines Resort, Malaysia.

Changsha Rongxi Biotechnology Co., Ltd., established on 2022-03-08, Business scope includes general items:Biochemical product technology research and development;Consulting and planning service;Corporate Image Planning;marketing planning;brand management;Business Management Consulting;Advertising Design,acting;advertisement making;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Digital cultural and creative content application services;Photographic Printing Services;Organize cultural and artistic exchange activities;Trademark agency;Anime Game Development;E-sports audio and video,Digitally Derived Content Production(Does not include publishing);Professional Design Services;business management;Remote Health Management Services;Cosmetics Retail;Personal Hygiene Sales;Clothing and apparel wholesale;Clothing and apparel retail.(Except for projects subject to approval by law,Independent development is not prohibited by laws and regulations,Unrestricted business activities)

Zhuji Weiyin Biotechnology Co., Ltd., established on 2011-08-23, The business scope includes biomedical testing clinical application hardware systems,Research on Application Software and Detection Reagents,to develop,Production;Software Products,Technology development of biomedical testing technologies and services,Technical Services,Achievement transfer;Biomedical Detection Technology,Automation Control System,Research and development of instrument equipment control system,Production;Sell ​​self-produced products(Certificate operation involving license)

Janssen Research & Development LLC, part of Johnson & Johnson, is a company headquartered in Raritan, NJ, that provides research and development medicines and solutions to other medical needs.\nThe company says this about itself: At Janssen, we are dedicated to addressing and solving some of the most important unmet medical needs of our time in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we develop innovative products, services and healthcare solutions to help people throughout the world. Janssen Research & Development is part of the Janssen Pharmaceutical Companies of Johnson & Johnson.